Skip to Content

Transgene SA TRGNF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. The firm is based in Strasbourg, France has additional operations in Lyon as well as satellite offices in China and United States. Its subsidiary represents the company before various bodies, regulatory authorities and clinical sites for clinical trials it conducts in the US.

Contact
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166
Illkirch-Graffenstaden, 67405, France
T +33 388279100
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2005
Fiscal Year End Dec 31, 2020
Stock Type
Employees 161